Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
HomeNews Center WIKIMOLE—Osimertinib

NEWS | 24 May 2024



By TargetMol


Osimertinib is an orally available, third-generation EGFR inhibitor (EGFR-TKI) widely used for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations.


EGFR (Epidermal Growth Factor Receptor) is the receptor for epidermal growth factor (EGF) involved in cell proliferation and signal transduction. It is also known as HER1 or ErbB1. The EGFR signaling network is highly complex and consists of multiple layers. The input layer includes receptors and ligands, while beneath the cell surface lies an intricate system of various enzymes, adaptor proteins, second messengers, and transcription factors. The output layer encompasses various cellular responses. In most cases, the ultimate result of EGFR activation is the stimulation of cell growth. Existing research has shown that activating mutations of the EGFR gene are key oncogenic drivers in non-small cell lung cancer (NSCLC).




The emergence of EGFR-TKIs in the early 21st century marked a paradigm shift in the management of EGFR mutation-positive NSCLC, heralding the advent of the era of precision medicine. Compared to traditional cytotoxic therapies, EGFR-TKIs have improved clinical outcomes and health-related quality of life for patients with advanced disease. However, acquired resistance to first-generation (e.g., erlotinib, gefitinib) and second-generation (e.g., afatinib, dacomitinib) EGFR-TKIs typically emerges after a median of 9-15 months, with the EGFR T790M mutation appearing to mediate resistance in approximately 50%-60% of patients.

Third-generation EGFR-TKIs were designed to selectively inhibit both the sensitizing and T790M resistance mutations of EGFR tyrosine kinase, while largely sparing wild-type EGFR activity, thereby reducing off-target toxicity compared to earlier EGFR-TKIs. Osimertinib, a third-generation EGFR inhibitor (EGFR-TKI), has been widely approved for the first-line treatment of advanced NSCLC with activating EGFR mutations, and has also shown potential efficacy against other types of EGFR mutation tumors in clinical trials. With a deeper understanding of resistance mechanisms and continuous innovation in therapeutic strategies, osimertinib’s position in lung cancer treatment is expected to further consolidate and expand.



[1] doi:10.1016/s0959-8049(01)00230-1

[2] doi:10.1007/s11523-021-00839-w

[3] doi: 10.1111/cas.15229.

[4] doi: 10.1038/s41598-024-58499-5.


Other Articles

Major Upgrade in Natural Product Library for HTS
EACR 2022 Congress